HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations.

Abstract
The GALNT3 gene encodes GalNAc-T3, which prevents degradation of the phosphaturic hormone, fibroblast growth factor 23 (FGF23). Biallelic mutations in either GALNT3 or FGF23 result in hyperphosphatemic familial tumoral calcinosis or its variant, hyperostosis-hyperphosphatemia syndrome. Tumoral calcinosis is characterized by the presence of ectopic calcifications around major joints, whereas hyperostosis-hyperphosphatemia syndrome is characterized by recurrent long bone lesions with hyperostosis. Here we investigated four patients with hyperphosphatemia and clinical manifestations including tumoral calcinosis and/or hyperostosis-hyperphosphatemia syndrome to determine underlying genetic cause and delineate phenotypic heterogeneity of these disorders. Mutational analysis of FGF23 and GALNT3 in these patients revealed novel homozygous mutations in GALNT3. Although the presence of massive calcifications, cortical hyperostosis, or dental anomalies was not shared by all patients, all had persistent hyperphosphatemia. Three of the patients also had inappropriately normal 1,25-dihyroxyvitamin D [1,25(OH)(2)D] and confirmed low circulating intact FGF23 concentrations. The four novel GALNT3 mutations invariably resulted in hyperphosphatemia as a result of low intact FGF23, but other clinical manifestations were variable. Therefore, tumoral calcinosis and hyperostosis-hyperphosphatemia syndrome represent a continuous spectrum of the same disease caused by increased phosphate levels, rather than two distinct disorders.
AuthorsShoji Ichikawa, Geneviève Baujat, Aksel Seyahi, Anastasia G Garoufali, Erik A Imel, Leah R Padgett, Anthony M Austin, Andrea H Sorenson, Zagorka Pejin, Vicken Topouchian, Pierre Quartier, Valerie Cormier-Daire, Michele Dechaux, Fotini Ch Malandrinou, Panagiotis N Singhellakis, Martine Le Merrer, Michael J Econs
JournalAmerican journal of medical genetics. Part A (Am J Med Genet A) Vol. 152A Issue 4 Pg. 896-903 (Apr 2010) ISSN: 1552-4833 [Electronic] United States
PMID20358599 (Publication Type: Case Reports, Journal Article, Research Support, N.I.H., Extramural)
Copyright(c) 2010 Wiley-Liss, Inc.
Chemical References
  • FGF23 protein, human
  • Fibroblast Growth Factor-23
  • N-Acetylgalactosaminyltransferases
  • polypeptide N-acetylgalactosaminyltransferase
Topics
  • Adolescent
  • Adult
  • Base Sequence
  • Calcinosis (complications, diagnostic imaging, enzymology, genetics)
  • Child
  • Child, Preschool
  • DNA Mutational Analysis
  • Family
  • Female
  • Fibroblast Growth Factor-23
  • Humans
  • Male
  • Molecular Sequence Data
  • Mutation (genetics)
  • N-Acetylgalactosaminyltransferases (genetics)
  • Neoplasms (complications, diagnostic imaging, enzymology, genetics)
  • Radiography
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: